; (II) the type of dispensing channel used to furnish such drug, including retail, mail order, or specialty pharmacy; (III) with respect to each drug dispensed under each type of dispensing channel (including retail, mail order, or specialty pharmacy)— (aa) whether such drug is a brand name drug or a generic drug, and— (AA) in the case of a brand name drug, the wholesale acquisition cost, listed as cost per days supply and cost per dosage unit, on the date such drug was dispensed; and (BB) in the case of a generic drug, the average wholesale price, listed as cost per days supply and cost per dosage unit, on the date such drug was dispensed; and (bb) the total number of— (AA) prescription claims (including original prescriptions and refills); (BB) participants, beneficiaries, and enrollees for whom a claim for such drug was filed; (CC) dosage units per fill of such drug; and (DD) days supply of such drug per fill; (IV) the net price per course of treatment or single fill, such as a 30-day supply or 90-day supply to the plan after manufacturer rebates, fees, and other remuneration or adjustments; (V) the total amount of out-of-pocket spending by participants, beneficiaries, and enrollees on such drug, including spending through copayments, coinsurance, and deductibles; (VI) the total net spending by the plan during the reporting period; (VII) the total amount received, or expected to be received, by the plan from any entity in drug manufacturer rebates, fees, alternative discounts, and all other remuneration received from an entity or any third party (including group purchasing organizations) other than the plan sponsor; (VIII) the total amount received, or expected to be received by the plan, from drug manufacturers in rebates, fees, alternative discounts, or other remuneration— (aa) that has been paid, or is to be paid, by drug manufacturers for claims incurred during the reporting period; and (bb) that is related to utilization rebates for such drug